Indian drugmaker Natco Pharma has filed a suit in the Delhi High Court seeking to revoke Novo Nordisk's patent for semaglutide, a diabetes medication. This follows a similar suit by Dr. Reddy's Laboratories. The court has issued a notice to Novo Nordisk, seeking its response. Novo Nordisk's patent is set to expire in March. The court previously found Dr. Reddy's had presented a credible challenge to the patent's validity.